with homogenates of cultured human skin fibroblasts has indirectly been shown to release GlcNAc6S and GalNAc6S respectively. Release of GalNAc4S could not be demonstrated in similar incubations of oligosaccharide substrates derived from chondroitin 4-sulphate and containing non-reducing-end fl-linked GalNAc4S residues. 4. We propose that some, if not all, of the sulphated N-acetylhexosamine present in human urine is derived from the action of P-N-acetylhexosaminidase on sulphated GlcNAc or GalNAc residues at the non-reducing end of keratan sulphate, dermatan sulphate or chondroitin sulphate.
It is known that there are five different sulphatase activities involved in the degradation of the sulphated glycosaminoglycans heparan sulphate (HS), dermatan sulphate (DS) and keratan sulphate (KS). A deficiency in any one of these sulphatase activities in humans leads to the accumulation in tissues, and the excretion, of abnormal amounts of HS, DS and/or KS and the expression of a group of lysosomal storage disorders known as the mucopolysaccharidoses (McKusick & Neufeld, 1983) . We have recently Abbreviations used: GIcNAc6S, N-acetylglucosamine 6-sulphate; GalNAc6S; N-acetylgalactosamine 6-sulphate; GalNAc4,6diS, N-acetylgalactosamine 4,6-disulphate; HS, heparan sulphate; DS, dermatan sulphate;
KS, keratan sulphate; MPS, mucopolysaccharidosis.
described the excretion of abnormnal amounts (>500-fold increase over normal) of the monosaccharide N-acetylglucosamine 6-sulphate (GlcNAc6S) in the urine of a patient with mucopolysaccharidosis Type IIID (N-acetylglucosamine-6-sulphate sulphatase-deficient; MPS IIID; Sanfilippo D Syndrome) (Hopwood & Elliott, 1983b) . This finding led us to speculate that this increased level of GlcNAc6S, which is not able to be further hydrolysed by these patients, may in part result from the action of the A form of fl-Nacetylhexosaminidase on the fl-linked GlcNAc6S residues at the non-reducing end of KS. It is not possible to connect directly the excessive excretion of GlcNAc6S in MPS IIID patients to KS catabolism, since several sulphated glycoproteins Vol. 229 have been described that also contain fl-linked GlcNAc6S residues and therefore may also be susceptible to hydrolysis by ,B-N-acetylhexosaminidase to produce GlcNAc6S. The finding of elevated levels of GlcNAc6S in urine from MPS IIID patients with a deficiency of N-acetylglucosamine-6-sulphate sulphatase lead us to investigate the sulphated N-acetylhexosamine content of urine from other N-acetylhexosamine sulphate sulphatase-deficient patients such as mucopolysaccharidosis Type IVA (MPS IVA; N-acetylgalactosamine-6-sulphate sulphatase-deficient; Morquio A Syndrome) and mucopolysaccharidosis Type VI (MPS VI; N-acetylgalactosamine-4-sulphate sulphatase-deficient; Maroteaux-Lamy Syndrome). We now report the isolation of other N-acetylhexosamine sulphate esters [N-acetylgalactosamine 4-sulphate (GalNAc4S) , N-acetylgalactosamine 6-sulphate (GalNAc6S), N-acetylgalactosamine 4,6-disulphate (GalNAc4,5diS)] from the urine of normal controls and a variety of mucopolysaccharidoses and other lysosomal-storage-disorder patients.
Experimental Materials
Radiolabelled GlcNAc6S (sp. radioactivity 60Ci/mol) was prepared from [1-14C]GlcNAc (The Radiochemical Centre, Amersham, Bucks., U.K.) by using a preparative method previously described (Hopwood & Elliott, 1981) . Radiolabelled GalNAc6S (sp. radioactivity 52Ci/mol) was prepared by O-sulphation from [1-14C]galactosamine hydrochloride (The Radiochemical Centre) after N-acetylation by using preparative methods previously described (Hopwood & Elliott, 1981) . Radiolabelled disulphated GlcNAc (GlcNAcdiS) was present in the GlcNAc sulphation mixture and separated from GlcNAc6S by descending paper chromatography in Solvent 1 [butan-l-ol/acetic acid/aq. NH3 (1 mol/l), 2 :3: 1 (by vol.)] for 20h at 25°C. Mobilities relative to GlcNAc were 0.66 for GlcNAc6S and 0.25 for the proposed disulphated GlcNAc component. Preparative high-voltage electrophoresis on Whatman 3MM paper in formic acid (1.75mol/l, pHl.7) at 45V/cm for 40min (Hopwood & Elliott, 1981) for the three major components separated in the above descending paper chromatography caused the proposed disulphated GlcNAc, GlcNAc6S and GlcNAc to migrate 19cm, 9.5cm and Ocm from the origin respectively. The disulphated GlcNAc is probably GlcNAc 3,6-disulphate (Ishihara et al., 1976a (Hopwood & Elliott, 1983a) . Chondroitin sulphate trisaccharide substrates ,B-GalNAc6S-,B-GlcA-[l-3H]N-acetylgalactosaminitol-6S (Substrate 2) and ,B-GalNAc4S -,f-GlcA[1 -3H]N-acetylgalactosaminitol-4S (Substrate 5) were prepared from chondroitin 6-sulphate and chondroitin 4-sulphate by the method previously described (Hopwood & Elliott, 1983c) . These trisaccharides were partially desulphated by enzyme digestion with homogenates of human skin fibroblasts at pH4.5 in the presence of 2-acetamido-2-deoxy-D-gluconolactone (1Ommol/litre) to produce the monosulphated trisaccharides j-GalNAc-fl-GlcA-[1-3H]N-acetylgalactosaminitol-6S (Substrate 3) and ,B-GalNAc-P-GlcA-[l-3H]N-acetylgalactosaminitol-4S (substrate 6). The specific radioactivity of the chondroitin 6-sulphate substrates was 250Ci/mol and of the chondroitin 4-sulphate substrates, 90 Ci/mol. P-GalNAc6S-P-Glc-[1 -3H]N-acetylgalactosaminitol-6S (Substrate 4) was prepared by carboxy group reduction of Substrate 2 by methods previously described (Hopwood & Elliott, 1983c (Pollard et al., 1980) and multiple sulphatase deficiencies. The samples were immediately frozen and stored at -20°C until used. Creatinine was determined as previously described at 4°C against 100 ml of water. The diffusate was concentrated by rotary evaporation at 250C to 10 ml, mixed with 50M1 of formic acid and applied to a column (l.5 cm x 7cm) of Dowex 50 (H+ form) equilibrated with formic acid (50mmol/l), which was then washed with 30ml of formic acid (50mmol/l). The break-through fraction plus the washings were combined, rotary-evaporated at 25°C to lOml, applied'to'a column (l.5 cm x 7cm) of Dowex 1 (Cl-form) and batch-eluted with 25 ml each of LiCl (0.3mol/1), LiCl (0.8mol/1) and LiCl (3.0mol/1). Fractions (5ml) were collected and assayed for radioactivity. Approx. 70% of the initial radioactivity was eluted within the first 15 ml of LiCl (0.8 mol/1) for urine samples containing [1-_4C]GlcNAc6S and within the first i5ml of LiCl (3mol/1) for urine 'spiked' with [1-14C]GlcNAcdiS. Fractions containing radioactivity were pooled, rotary-evaporated at 250C to approx. 1 ml, desalted on a column (1.6cm x 100 cm) of Sephadex G-10 in aq. 10% (v/v) ethanol, freeze-dried, dissolved in IOOpl of water and subjected to preparative descending paper chromatography on Whatman 3MM paper with development in Solvent 1 at 250C for 17h. Radioactive material corresponding to the 14C-labelled sulphated Nacetylhexosamine standards, located by using a Packard radiochromatogram scanner (Hopwood & Elliott, 1981) and/or GalNAc6S and GalNAc4S standards located by using alkaline AgNO3, were eluted with water and rotary-evaporated to a total volume of 100 p1. Recovery of radioactive material to this stage varied from 9 to 50% of the 14C-labelled sulphated N-acetylhexosamines added to the initial urine sample. Half (50jil) was acidhydrolysed in 2ml of HCI (4mol/1) at 100°C under N2 for 6 h. The extent of de-N-acetylation and de-O-sulphation of the radiolabelled standard was monitored by high-voltage electrophoresis of 40pl of hydrolysate at pH 1.7 in formic acid (1.75 mol/1) as described above.
The (Fig. 2) .
As we have previously reported (Hopwood & Elliott, 1983b) , the level of GlcNAc6S in urine from patients with a deficiency of N-acetylglucosamine 6-sulphate sulphatase (MPS IIID) shows a morethan-300-fold elevation ( Distance from origin (cm) Fig. 1 Urine from a multiple-sulphatase-deficient patient compared with normal contained 76-, 68-, 17-and 10-fold-elevated levels of GlcNAc6S, GalNAc6S, GalNAc4S and GalNAc4,6diS respectively. A mucolipidosis-Type-II patient excreted slightly increased levels of GalNAc6S and GalNAc4S and 20-fold higher amounts of GalNAc-4,6diS, whereas urine from a clinically severe amannosidosis patient contained normal levels of all four sulphated N-acetylhexosamines (Table 1) . Incubations offibroblast homogenates with sulphated oligosaccharide substrates
Hydrolysis of the non-reducing-end sulphated N-acetylhexosamine residues of oligosaccharide substrates by homogenates of cultured skin fibroblasts produced two product types (see Table 2 ). Product type 1 results from the action of a specific sulphatase, whereas product type 2 results from the action of ,B-N-acetylhexosaminidase, either directly on the ,B-glycosidic linkage of the sulphated Nacetylhexosamine residue or on the unsulphated N-acetylhexosamine residue (product 1) resulting from the action of the sulphatase (Scheme 1). We have previously shown that the addition of the ,B-N-acetylhexosaminidase inhibitor 2-acetoamido-2-deoxy-D-glucolactone and incubation in sodium acetate buffer (50mmol/l) results in the complete inhibition of f-N-acetylhexosaminidase activity towards Substrate 1 and 2 and their partially desulphated equivalents (Hopwood & Elliott, 1983a) . Further degradation of f,-N-acetylhexosaminidase products (type 2) of the chondroitin sulphate-derived substrates was inhibited by the addition of the ,B-glucuronidase inhibitor D-saccharic acid 1,4-lactone to these incubation mixtures. Significant degradation of the f-N-acetylhexosaminidase product of KS-derived Substrate 1 by galactose-6-sulphate sulphatase is unlikely, since this enzyme is relatively inactive toward these substrates under the conditions studied (Hopwood & Elliott, 1983c) .
Results recorded in Table 3 show that f-Nacetylhexosaminidase in fibroblast homogenates is most active towards Substrate 1, producing GlcNAc6S and radiolabelled fl-Gal6S-/-GlcNAc6S-galactitol. In the presence of the ,B-N-acetylhexosaminidase inhibitor the relatively low level of sulphatase product (type 1) is not altered, but Vol. 229 
(Product type 2) Scheme 1. Proposed pathways for exodegradation of fl-linked sulphated N-acetylhexosamine residues of, for example, the trisaccharide (Substrate 2) derived from chondroitin 6-sulphate the level of fB-N-acetylhexosaminidase product -(type 2) is less than 1% of the inhibitor-free incubation mixtures. Normal levels of type 2 product in the absence of sulphatase product (type 1) were observed when Substrate 1 was incubated with homogenates from MPS IIID (N-acetylglucosamine-6-sulphate sulphatase-deficient) fibroblasts (Hopwood & Elliott, 1983a) . .Type 1 and 2 products are also observed in normal control fibroblast homogenate incubations with Substrate 2. (Table 3) . Under conditions where P-N-acetylhexosaminidase is inhibited, the level of type 1 product is increased and type 2 product considerably decreased. Fibroblasts from MPS IVA patients incubated with Substrate 2 produce detectable, but very low, levels of type 2 product in the absence of detectable levels of product 1. Products 1 and 2 were not detectable in incubations of MPS IVA fibroblasts with Substrate 2 in the presence of the P-N-acetylhexosaminidase inhibitor. Except for a 4-fold increase in the level of type 2 product, a similar result was observed for Substrate 4, a carboxy-group-reduced equivalent of Substrate 2. These results suggest that the fl-N-acetylhexosaminidase activity in cultured fibroblasts is able to cleave the glycosidic bond of the non-reducing-end GalNAc6S residues to yield, presumably, unlabelled GalNAc6S and labelled type 2 product without the sequential action of sulphatase to product 1, which is then hydrolysed by ,B-N-acetylhexosaminidase to product 2. The action of the N-acetylgalactosamine-6-sulphate sulphatase activities of MPS VI and normal fibroblasts on Substrate 2 to yield its product seem to proceed at approximately the same rate as the action of P-N-acetylhexosaminidase on product 1 produced either in situ from Substrate 2 incubations or in separate incubations ,-N-Acetylhexosaminidase inhibitor 2-acetoamido-2-deoxy-D-glucolactone (5 mmol/l).
t Type 2 product results from the action of either P-N-acetylhexosaminidase or a sequence of sulphatase and then P-Nacetylhexosaminidase.
I Type 1 product results from the action of sulphatase only.
with Substrate 3. However, the activity of ,B-Nacetylhexosaminidase in MPS IVA fibroblasts towards GalNAc6S glycosidic bonds in Substrate 2 is more than 300 times less than its activity towards the fl-linked GalNAc residue in Substrate 3 (Table  3) .
Substrate 5, the 4-sulphate ester equivalent to Substrate 2, was desulphated by fibroblasts from normal individuals and MPS IVA patients to a type 1 product at a rate approx. 10 times less than that observed for the 6-sulphated ester equivalent (Table 3) . Hydrolysis of the type 1 product of Substrate 5 to a type 2 product by the action of fl-Nacetylhexosaminidase was observed for incubations containing MPS IVA or normal fibroblast homogenates. Hydrolysis of Substrate 5 by either the action of sulphatase or fl-N-acetylhexosaminidase to type 1 and/or 2 products was not observed in incubations using MPS VI fibroblast homogenates (Table 3) . However, incubation of Substrate 6 (type 1 product of Substrate 5) with MPS IVA or VI fibroblast homogenates gave a type 2 product at a rate approx. 10 times less than that observed with Substrate 3.
Discussion
The source of the sulphated N-acetylhexosamines (GlcNAc6S, GalNAc6S, GalNAc4S and GalNAc4,6diS) in normal urine is not known. Sulphated N-acetylhexosamines have been identified as being integral parts of sulphated glycosaminoglycans, glycoproteins and sugar nucleotides. We have previously proposed that GlcNAc6S in urine may result from the action of f-N-acetylhexosaminidase on P-linked GlcNAc6S residues at non-reducing ends of KS chains and/or sulphated oligosaccharides of glycoproteins (Hopwood & Elliott, 1983a,b) . We have previously reported that N-acetylglucosamine-6-sulphate sulphatase, which is deficient in MPS IIID fibroblasts, specifically desulphates both a-and fl-linked GlcNAc6S residues at the non-reducing end of HS and KS respectively (Hopwood & Elliott, 1983a (Hopwood & Elliott, 1983a,b) . As KS is not present above normal levels in MPS IIID urine, it has been proposed that, in these patients, fl-linked GlcNAc6S residues in KS are degraded by the action of P-N-acetylhexosaminidase (type A) to produce the monosaccharide GlcNAc6S, which will not de-O-sulphate and will therefore accumulate in tissues and be excreted in excess by these patients. Thus the GlcNAc6S monosaccharide present in MPS IIID urine may be considered as representing the block in KS degradation. By similar logic, the excretion of large amounts of GalNAc6S in urine from MPS IVA patients and GalNAc4S and GalNAc4,6diS in the urine of MPS VI patients could be expected to result from the action of,-N-acetylhexosaminidase on chondroitin sulphate and DS, which accumulate in Vol. 229 585 2 5 these patients. Obviously, as 6-sulphated or 4-sulphated galactosaminoglycans accumulate in MPS IVA or MPS VI patients the efficiency of,f-N-acetylhexosaminidase towards fl-linked sulphated GalNAc residues must be much lower than that observed towards non-reducing-end fl-linked GlcNAc6S residues in KS. Results reported in Table 3 show that the #-N-acetylhexosaminidase activity towards the non-reducing-end GalNAc6S glycosidic bond in Substrate 2 is approx. 750 times less than that towards P-linked GlcNAc6S in the KS Substrate 1. This difference is not totally due to the carboxyl group on the adjacent GlcA residue, since its reduction to Glc leads to only a 4-fold increased hydrolysis of the GalNAc6S glycosidic bond (Substrate 4, Table 3 ). The other differences, fl-1,4-linked GalNAc components in chondroitin sulphate in place of f-1,3-linked GlcNAc residues adjacent to P-linked galactose residues (which may also be C-6-sulphated in KS), may provide the structural requirement for more efficient f-Nacetylhexosaminidase cleavage of sulphated Nacetylhexosamines. We have previously reported that P-linked GlcNAc6S residues in the tetrasaccharide Substrate 1 are hydrolysed by P-Nacetylhexosaminidase at a rate 400 times higher than that observed for a disaccharide, fiGlcNAc6S[1-3H]galactitol (Hopwood & Elliott, 1983a ). This result suggests that P-N-acetylhexosaminidase hydrolysis of these substrates may be influenced by adjacent-residue C-6 sulphate esters, intact adjacent-residue galactose ring or a requirement for a second GlcNAc6S residue two residues removed from the bond under P-N-acetylhexos aminidase attack. Preliminary studies have shown that the activity of fl-N-acetylhexosaminidase towards ,B-1,3 GlcNAc6S residues is increased 40-fold by the presence of C-6 sulphate esters on the adjacent galactose residue in KS tetrasaccharide structures of Substrate 1 type (Hopwood & Elliott, 1983d) .
Cleavage of fl-linked GalNAc4S residues was not observed from Substrate 5 under conditions similar to those used with Substrate 2 (Table 2) .
Increased concentration of GalNAc4,6diS in urine from MPS VI and not MPS IVA patients suggests that the de-O-sulphation of this compound proceeds sequentially, first with the 4-sulphate sulphatase (deficient in MPS VI) to produce GalNAc6S, which is then de-O-sulphated by the 6-sulphate sulphatase (deficient in MPS IVA) to produce GalNAc. The finding of sulphated N-acetylhexosamines in urine suggests that these monosaccharide sulphates are probably, along with the relevant sulphated glycosaminoglycans, the substrates in vivo for their respective sulphatases.
It would appear that the data reported in Table 3 are consistent with the proposal that GlcNAc6S and GalNAc6S may, in part, result from the action of P-N-acetylhexosaminidase on KS and chondroitin 6-sulphate respectively. The presence of GalNAc4S, GalNAc6S and GalNAc4,6diS in rat urine has been connected indirectly to the synthesis and turnover of UDP-N-acetylgalactosamine 4,6-disulphate (Ishihara et al., 1976a,b) . It is also possible that sulphated N-acetylhexosamines may result from the action of P-N-acetylhexosaminidase towards the sulphated oligosaccharide moiety of glycoproteins that have been shown to contain GlcNAc6S or GalNAc6S (Liau & Horowitz, 1983) . Proof of the source of the four sulphated Nacetylhexosamines identified in human urine (Table 1 ) will have to await further studies into the catabolism of sulphated glycosaminoglycans, glycoproteins and sugar nucleotides.
